85 results on '"Avvisati G"'
Search Results
2. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
3. Insight into the electronic structure of semiconducting ε−GaSe and ε−InSe
4. Molecular Diagnosis and Monitoring of Acute Promyelocytic Leukemia: Updated Results of the Italian Gimema Group
5. PB2386 BEHAVIOUR OF CIRCULATING ENDOTHELIAL CELLS IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
6. EP-1252: Dosimetric and clinical outcomes of radiotherapy for early-stage lymphoma mediastinal involvement
7. PD-1 /PD-L1 checkpoint in hematological malignancies
8. PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
9. Alkaline Phosphatase (ALP) Levels in Multiple Myeloma (MM) And Cancer With Bone Lesions : Is There any Difference?
10. C0382 The role of thrombophilia in the perinatal stroke in neonates: A retrospective study in 54 cases
11. Tuberculous Meningoencephalitis in a Patient with Hairy Cell Leukemia in Complete Remission
12. Foetal Haemoglobin, Erythrocytes Containing Foetal Haemoglobin, and Hematological Features in Congolese Patients with Sickle Cell Anaemia
13. Sytemic strongyloidiasis and primary aspergillosis of digestive tract in a patient with T-cell acute lymphoblastic leukemia
14. Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4Positive B-Cell Acute Lymphoblastic Leukemia
15. Interferon: A new strategy in the treatment of multiple myeloma
16. High-dose ARA-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: A pilot multicentric study by the Italian cooperative group GIMEMA
17. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment
18. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA
19. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin
20. A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp
21. La función de la eritropoyetina en pacientes sometidos a artroplastia articular electiva y a donación de sangre autóloga preoperatoria
22. Erythropoietin in Patients Undergoing Elective Joint Arthroplasty and Preoperative Autologous Blood Donation
23. Triazene compounds: Mechanism of action and related DNA repair systems
24. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
25. Angiogenesis modifications are predictive of response and outcome in heavily pretreated advanced colorectal cancer patients during therapy with cetuximab plus irinotecan
26. Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.
27. Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).
28. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results
29. Neoadjuvant chemoradiotherapy followed by surgery in elderly patients with locally advanced Non-Small Cell Lung Cancer: Analysis of feasibility, toxicity and factors predicting surgical resection and survival
30. Neoadjuvant chemoradiotherapy followed by surgery in elderly patients with locally advanced Non-Small Cell Lung Cancer: Analysis of feasibility, toxicity and factors predicting surgical resection and survival
31. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients (Br J Surg 2003; 90: 547-548)
32. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
33. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up
34. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia
35. Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia
36. Pamidronate (P) induces modifications of circulating angiogenetic factors in cancer patients
37. Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy in Patients with Acute Emesis
38. Acute promyelocytic leukemia: a curable disease
39. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–1991)
40. All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase
41. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years
42. 69 Spontaneous improvement of hematological parameters in 8 patients with myelodysplastic syndromes (MDS)
43. 64 Myelodysplastic syndromes (MDS) in patients aged>20 and <40 years
44. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia
45. Meningeal localization in a patient with Hodgkin's disease. Description of a case and review of the literature
46. Treatment of high‐risk myelodysplastic syndromes with lymphoblastoid alpha interferon
47. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study
48. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase
49. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase
50. On the differentiative mode of action of All-trans retinoic acid in acute promyelocytic leukemia [letter; comment]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.